Browse by author
Lookup NU author(s): Dr Jonathan Smout,
Dr Brian Shenton,
Professor Gerard Stansby
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Peripheral bypass graft occlusion occurs in approximately 25% of cases in the 5 years following surgery; hence, therapies directed at reducing the tendency toward thrombotic occlusion are of clinical importance. This trial was conducted to determine if the addition of clopidogrel to aspirin enhances antiplatelet therapy in patients with infrainguinal bypass grafts. A randomized placebo-controlled study was performed on 20 patients over 3 months following infrainguinal bypass surgery. In addition to their regular aspirin therapy, patients were randomized to receive either clopidogrel (group 1) or placebo (group 2) for 1 week. Platelet activation was measured ex vivo by platelet aggregometry and flow cytometry. In group 1, there was a significant reduction in spontaneous (SP), adenosine diphosphate (ADP), and arachidonic acid (AA)-induced platelet aggregation compared with group 2; SP -17% (CI -33, -0.2 p = 0.048), ADP -39%, (CI -56, -22 p = 0.001), AA -21% (CI -39, -4 p = 0.023). Flow cytometry demonstrated a significant reduction in ADP-induced platelet P-selectin expression and GPIIb/IIIa activation following treatment with clopidogrel but not with placebo. This study demonstrated that the addition of clopidogrel to aspirin reduces platelet activation measured by platelet aggregation and flow cytometry, supporting a long-term trial with clinical endpoints.
Author(s): Smout JD, Mikhailidis DP, Shenton BK, Stansby G
Publication type: Article
Publication status: Published
Journal: Clinical and Applied Thrombosis/Hemostasis
Print publication date: 01/01/2004
ISSN (print): 1076-0296
ISSN (electronic): 1938-2723
PubMed id: 14979400
Altmetrics provided by Altmetric